Clumping factor A interaction with complement factor I increases C3b cleavage on the bacterial surface of Staphylococcus aureus and decreases complement-mediated phagocytosis. 2010

Pamela S Hair, and Charlene G Echague, and Amber M Sholl, and Justin A Watkins, and Joan A Geoghegan, and Timothy J Foster, and Kenji M Cunnion
Department of Pediatrics, Eastern Virginia Medical School, Norfolk, Virginia, USA.

The human complement system is important in the immunological control of Staphylococcus aureus infection. We showed previously that S. aureus surface protein clumping factor A (ClfA), when expressed in recombinant form, bound complement control protein factor I and increased factor I cleavage of C3b to iC3b. In the present study, we show that, compared to the results for the wild type, when isogenic ClfA-deficient S. aureus mutants were incubated in serum, they bound less factor I, generated less iC3b on the bacterial surface, and bound fewer C3 fragments. It has been shown previously that two amino acids in ClfA (P(336) and Y(338)) are essential for fibrinogen binding. However, S. aureus expressing ClfA(P336A Y338S) was less virulent than ClfA-deficient strains in animal models. This suggested that ClfA contributed to S. aureus virulence by a mechanism different than fibrinogen binding. In the present study, we showed that S. aureus expressing ClfA(P336A Y338S) was more susceptible to complement-mediated phagocytosis than a ClfA-null mutant or the wild type. Unlike ClfA, ClfA(P336A Y338S) did not enhance factor I cleavage of C3b to iC3b and inhibited the cofactor function of factor H. Fibrinogen enhanced factor I binding to ClfA and the S. aureus surface. Twenty clinical S. aureus strains all expressed ClfA and bound factor I. High levels of factor I binding by clinical strains correlated with poor phagocytosis. In summary, our results suggest that the interaction of ClfA with factor I contributes to S. aureus virulence by a complement-mediated mechanism.

UI MeSH Term Description Entries
D009504 Neutrophils Granular leukocytes having a nucleus with three to five lobes connected by slender threads of chromatin, and cytoplasm containing fine inconspicuous granules and stainable by neutral dyes. LE Cells,Leukocytes, Polymorphonuclear,Polymorphonuclear Leukocytes,Polymorphonuclear Neutrophils,Neutrophil Band Cells,Band Cell, Neutrophil,Cell, LE,LE Cell,Leukocyte, Polymorphonuclear,Neutrophil,Neutrophil Band Cell,Neutrophil, Polymorphonuclear,Polymorphonuclear Leukocyte,Polymorphonuclear Neutrophil
D010587 Phagocytosis The engulfing and degradation of microorganisms; other cells that are dead, dying, or pathogenic; and foreign particles by phagocytic cells (PHAGOCYTES). Phagocytoses
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D003030 Coagulase Enzymes that cause coagulation in plasma by forming a complex with human PROTHROMBIN. Coagulases are produced by certain STAPHYLOCOCCUS and YERSINIA PESTIS. Staphylococci produce two types of coagulase: Staphylocoagulase, a free coagulase that produces true clotting of plasma, and Staphylococcal clumping factor, a bound coagulase in the cell wall that induces clumping of cells in the presence of fibrinogen. Staphylocoagulase,Staphylococcal Clumping Factor,Clumping Factor (Staphylococcal),Staphylococcus aureus clone pSCa2 of Coagulase,Staphylococcus aureus strain 213 of Coagulase,Staphylococcus aureus strain 8325-4 of Coagulase,Clumping Factor, Staphylococcal,Factor, Staphylococcal Clumping,Staphylococcus aureus strain 8325 4 of Coagulase
D003179 Complement C3b The larger fragment generated from the cleavage of COMPLEMENT C3 by C3 CONVERTASE. It is a constituent of the ALTERNATIVE PATHWAY C3 CONVERTASE (C3bBb), and COMPLEMENT C5 CONVERTASES in both the classical (C4b2a3b) and the alternative (C3bBb3b) pathway. C3b participates in IMMUNE ADHERENCE REACTION and enhances PHAGOCYTOSIS. It can be inactivated (iC3b) or cleaved by various proteases to yield fragments such as COMPLEMENT C3C; COMPLEMENT C3D; C3e; C3f; and C3g. C3b Complement,C3bi,Complement 3b,Complement Component 3b,Inactivated C3b,iC3b,C3b, Complement,C3b, Inactivated,Complement, C3b,Component 3b, Complement
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006868 Hydrolysis The process of cleaving a chemical compound by the addition of a molecule of water.
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013211 Staphylococcus aureus Potentially pathogenic bacteria found in nasal membranes, skin, hair follicles, and perineum of warm-blooded animals. They may cause a wide range of infections and intoxications.
D017244 Complement Factor I A plasma serine proteinase that cleaves the alpha-chains of C3b and C4b in the presence of the cofactors COMPLEMENT FACTOR H and C4-binding protein, respectively. It is a 66-kDa glycoprotein that converts C3b to inactivated C3b (iC3b) followed by the release of two fragments, C3c (150-kDa) and C3dg (41-kDa). It was formerly called KAF, C3bINF, or enzyme 3b inactivator. C3b Inactivator,C3b-C4b Inactivator,C4b-C3b-INA,C4bC3bINA,Complement 3b-Complement 4b Inactivator,Complement C4b-C3b Inactivator,C3b C4b Inactivator,C4b C3b INA,C4b-C3b Inactivator, Complement,Complement 3b Complement 4b Inactivator,Complement C4b C3b Inactivator,Inactivator, C3b,Inactivator, C3b-C4b,Inactivator, Complement C4b-C3b

Related Publications

Pamela S Hair, and Charlene G Echague, and Amber M Sholl, and Justin A Watkins, and Joan A Geoghegan, and Timothy J Foster, and Kenji M Cunnion
July 2008, The Journal of infectious diseases,
Pamela S Hair, and Charlene G Echague, and Amber M Sholl, and Justin A Watkins, and Joan A Geoghegan, and Timothy J Foster, and Kenji M Cunnion
May 2004, Infection and immunity,
Pamela S Hair, and Charlene G Echague, and Amber M Sholl, and Justin A Watkins, and Joan A Geoghegan, and Timothy J Foster, and Kenji M Cunnion
November 2005, The Journal of laboratory and clinical medicine,
Pamela S Hair, and Charlene G Echague, and Amber M Sholl, and Justin A Watkins, and Joan A Geoghegan, and Timothy J Foster, and Kenji M Cunnion
August 1975, Zentralblatt fur Bakteriologie, Parasitenkunde, Infektionskrankheiten und Hygiene. Erste Abteilung Originale. Reihe A: Medizinische Mikrobiologie und Parasitologie,
Pamela S Hair, and Charlene G Echague, and Amber M Sholl, and Justin A Watkins, and Joan A Geoghegan, and Timothy J Foster, and Kenji M Cunnion
May 2006, FEMS microbiology letters,
Pamela S Hair, and Charlene G Echague, and Amber M Sholl, and Justin A Watkins, and Joan A Geoghegan, and Timothy J Foster, and Kenji M Cunnion
September 1985, Infection and immunity,
Pamela S Hair, and Charlene G Echague, and Amber M Sholl, and Justin A Watkins, and Joan A Geoghegan, and Timothy J Foster, and Kenji M Cunnion
January 2013, PLoS pathogens,
Pamela S Hair, and Charlene G Echague, and Amber M Sholl, and Justin A Watkins, and Joan A Geoghegan, and Timothy J Foster, and Kenji M Cunnion
July 1997, European journal of biochemistry,
Pamela S Hair, and Charlene G Echague, and Amber M Sholl, and Justin A Watkins, and Joan A Geoghegan, and Timothy J Foster, and Kenji M Cunnion
April 1985, Acta pathologica, microbiologica, et immunologica Scandinavica. Section C, Immunology,
Pamela S Hair, and Charlene G Echague, and Amber M Sholl, and Justin A Watkins, and Joan A Geoghegan, and Timothy J Foster, and Kenji M Cunnion
July 2007, Infection and immunity,
Copied contents to your clipboard!